1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Eculizumab Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 Original Drug
  • 1.3.3 Biosimilar
• 1.4 Market Analysis by Application
  • 1.4.1 Overview: Global Eculizumab Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.4.2 PNH
  • 1.4.3 aHUS
  • 1.4.4 gMG
  • 1.4.5 Others
• 1.5 Global Eculizumab Market Size & Forecast
  • 1.5.1 Global Eculizumab Consumption Value (2021 & 2025 & 2032)
  • 1.5.2 Global Eculizumab Sales Quantity (2021-2032)
  • 1.5.3 Global Eculizumab Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 Alexion Pharmaceuticals
  • 2.1.1 Alexion Pharmaceuticals Details
  • 2.1.2 Alexion Pharmaceuticals Major Business
  • 2.1.3 Alexion Pharmaceuticals Eculizumab Product and Services
  • 2.1.4 Alexion Pharmaceuticals Eculizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 Alexion Pharmaceuticals Recent Developments/Updates
• 2.2 Amgen
  • 2.2.1 Amgen Details
  • 2.2.2 Amgen Major Business
  • 2.2.3 Amgen Eculizumab Product and Services
  • 2.2.4 Amgen Eculizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.2.5 Amgen Recent Developments/Updates
• 2.3 Samsung Bioepis
  • 2.3.1 Samsung Bioepis Details
  • 2.3.2 Samsung Bioepis Major Business
  • 2.3.3 Samsung Bioepis Eculizumab Product and Services
  • 2.3.4 Samsung Bioepis Eculizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.3.5 Samsung Bioepis Recent Developments/Updates

3 Competitive Environment: Eculizumab by Manufacturer

• 3.1 Global Eculizumab Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Eculizumab Revenue by Manufacturer (2021-2026)
• 3.3 Global Eculizumab Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Eculizumab by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Eculizumab Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Eculizumab Manufacturer Market Share in 2025
• 3.5 Eculizumab Market: Overall Company Footprint Analysis
  • 3.5.1 Eculizumab Market: Region Footprint
  • 3.5.2 Eculizumab Market: Company Product Type Footprint
  • 3.5.3 Eculizumab Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Eculizumab Market Size by Region
  • 4.1.1 Global Eculizumab Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Eculizumab Consumption Value by Region (2021-2032)
  • 4.1.3 Global Eculizumab Average Price by Region (2021-2032)
• 4.2 North America Eculizumab Consumption Value (2021-2032)
• 4.3 Europe Eculizumab Consumption Value (2021-2032)
• 4.4 Asia-Pacific Eculizumab Consumption Value (2021-2032)
• 4.5 South America Eculizumab Consumption Value (2021-2032)
• 4.6 Middle East & Africa Eculizumab Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Eculizumab Sales Quantity by Type (2021-2032)
• 5.2 Global Eculizumab Consumption Value by Type (2021-2032)
• 5.3 Global Eculizumab Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Eculizumab Sales Quantity by Application (2021-2032)
• 6.2 Global Eculizumab Consumption Value by Application (2021-2032)
• 6.3 Global Eculizumab Average Price by Application (2021-2032)

7 North America

• 7.1 North America Eculizumab Sales Quantity by Type (2021-2032)
• 7.2 North America Eculizumab Sales Quantity by Application (2021-2032)
• 7.3 North America Eculizumab Market Size by Country
  • 7.3.1 North America Eculizumab Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Eculizumab Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Eculizumab Sales Quantity by Type (2021-2032)
• 8.2 Europe Eculizumab Sales Quantity by Application (2021-2032)
• 8.3 Europe Eculizumab Market Size by Country
  • 8.3.1 Europe Eculizumab Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Eculizumab Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Eculizumab Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Eculizumab Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Eculizumab Market Size by Region
  • 9.3.1 Asia-Pacific Eculizumab Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Eculizumab Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Eculizumab Sales Quantity by Type (2021-2032)
• 10.2 South America Eculizumab Sales Quantity by Application (2021-2032)
• 10.3 South America Eculizumab Market Size by Country
  • 10.3.1 South America Eculizumab Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Eculizumab Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Eculizumab Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Eculizumab Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Eculizumab Market Size by Country
  • 11.3.1 Middle East & Africa Eculizumab Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Eculizumab Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Eculizumab Market Drivers
• 12.2 Eculizumab Market Restraints
• 12.3 Eculizumab Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Eculizumab and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Eculizumab
• 13.3 Eculizumab Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Eculizumab Typical Distributors
• 14.3 Eculizumab Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Eculizumab market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Eculizumab is a monoclonal antibody that inhibits complement protein C5, blocking the formation of the membrane attack complex (MAC) and preventing immune-mediated cell destruction. It is primarily used to treat rare diseases such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD).
This report is a detailed and comprehensive analysis for global Eculizumab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Eculizumab market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Eculizumab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Eculizumab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Eculizumab market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Eculizumab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Eculizumab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Alexion Pharmaceuticals, Amgen, Samsung Bioepis, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Eculizumab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Original Drug
Biosimilar
Market segment by Application
PNH
aHUS
gMG
Others
Major players covered
Alexion Pharmaceuticals
Amgen
Samsung Bioepis
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Eculizumab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Eculizumab, with price, sales quantity, revenue, and global market share of Eculizumab from 2021 to 2026.
Chapter 3, the Eculizumab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Eculizumab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Eculizumab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Eculizumab.
Chapter 14 and 15, to describe Eculizumab sales channel, distributors, customers, research findings and conclusion.